VRTX:NGS-Vertex Pharmaceuticals Incorporated (USD)

EQUITY | Biotechnology | Nasdaq Global Select

Last Closing

USD 462.11

Change

+3.11 (+0.68)%

Market Cap

USD 21.38B

Volume

1.41M

Analyst Target

USD 306.43
Analyst Rating

Verdict

ducovest Verdict

Verdict

About

Vertex Pharmaceuticals Inc is engaged in the business of discovering, developing, manufacturing and commercializing small molecule drugs for patients with serious diseases in specialty markets.

Unadjusted Closing Price

Adjusted Closing Price

Share Volume

Relative Performance (Total Returns)

Compare
Relative Returns (From:    To: 2025-02-18 )

Largest Industry Peers for Biotechnology

Symbol Name Price(Change) Market Cap
REGN Regeneron Pharmaceuticals Inc

+5.66 (+0.83%)

USD 73.95B
ARGX argenx NV ADR

+1.14 (+0.18%)

USD 40.41B
ALNY Alnylam Pharmaceuticals Inc

+0.51 (+0.20%)

USD 34.99B
ONC BeiGene, Ltd.

-1.42 (-0.60%)

USD 25.62B
RPRX Royalty Pharma Plc

-0.26 (-0.79%)

USD 18.65B
SMMT Summit Therapeutics PLC

+0.52 (+2.47%)

USD 17.52B
UTHR United Therapeutics Corporatio..

+7.95 (+2.13%)

USD 15.68B
INCY Incyte Corporation

-1.11 (-1.56%)

USD 14.29B
INSM Insmed Inc

+2.47 (+3.04%)

USD 13.70B
MRNA Moderna Inc

+0.15 (+0.42%)

USD 12.93B

ETFs Containing VRTX

DCCHAS:SW UBS (Irl) Fund Solutions .. 90.84 % 0.00 %

+0.82 (+0.11%)

USD 0.08B
DCUSAS:SW UBS (Irl) Fund Solutions .. 90.84 % 0.00 %

+1.29 (+0.11%)

N/A
DCEUAS:SW UBS (Irl) Fund Solutions .. 90.84 % 0.00 %

+0.89 (+0.11%)

N/A
DCGBAS:SW UBS (Irl) Fund Solutions .. 90.84 % 0.00 %

N/A

N/A
2B70:F 8.36 % 0.00 %

N/A

N/A
2B70:XETRA 8.36 % 0.00 %

N/A

N/A
MSGR 8.22 % 0.00 %

N/A

N/A
IBB iShares Biotechnology ETF 8.17 % 0.47 %

+1.63 (+0.11%)

USD 6.39B
CURE:XETRA 7.99 % 0.00 %

N/A

N/A
BTEC:SW iShares Nasdaq US Biotech.. 7.95 % 0.00 %

+0.01 (+0.11%)

N/A
CURG:LSE VanEck Genomics and Healt.. 7.66 % 0.00 %

+0.27 (+0.11%)

USD 5.28M
IBBQ Invesco Nasdaq Biotechnol.. 7.45 % 0.00 %

+0.22 (+0.11%)

USD 0.04B
BIS ProShares UltraShort Nasd.. 7.21 % 0.95 %

-0.30 (0.11%)

USD 3.30M
UBIO 6.52 % 0.95 %

N/A

N/A
DBPD:XETRA 6.32 % 0.00 %

N/A

N/A
BIB ProShares Ultra Nasdaq Bi.. 6.04 % 0.95 %

+0.99 (+0.11%)

USD 0.06B
LIFE-B:CA Evolve Global Healthcare .. 5.49 % 0.00 %

N/A

N/A
ZWHC:CA BMO Covered Call Health C.. 5.16 % 0.00 %

+0.34 (+0.11%)

N/A
LIFE-U:CA Evolve Global Healthcare .. 5.00 % 0.00 %

N/A

N/A
XGES:LSE Xtrackers MSCI Genomic He.. 4.94 % 0.00 %

+0.20 (+0.11%)

N/A
XGEN:XETRA 4.91 % 0.00 %

N/A

N/A
XNNS:LSE Xtrackers MSCI Innovation.. 4.83 % 0.00 %

+0.10 (+0.11%)

N/A
XNNV:LSE Xtrackers MSCI Innovation.. 4.83 % 0.00 %

-0.04 (0.11%)

N/A
XNNV:XETRA 4.76 % 0.00 %

N/A

N/A
FBT:LSE First Trust Global Funds .. 3.66 % 0.00 %

+14.90 (+0.11%)

USD 8.65M
FBTU:LSE First Trust Global Funds .. 3.66 % 0.00 %

+0.07 (+0.11%)

USD 8.62M
HEAL:CA 3.39 % 0.00 %

N/A

N/A
BIOT:SW L&G Pharma Breakthrough U.. 2.68 % 0.00 %

N/A

N/A
CDNA:CA CI Bio-Revolution Index E.. 2.50 % 0.00 %

+0.15 (+0.11%)

CAD 6.78M
UPWD 2.43 % 0.00 %

N/A

N/A
POWA Invesco Bloomberg Pricing.. 2.11 % 0.00 %

+0.33 (+0.11%)

N/A
MTUSD:PA BNP Paribas Easy ECPI Glo.. 2.10 % 0.00 %

-0.01 (0.11%)

N/A
SAGP The Advisorsa Inner Circl.. 2.09 % 0.00 %

-0.24 (0.11%)

USD 0.04B
QQXT First Trust NASDAQ-100 Ex.. 1.96 % 0.60 %

+0.03 (+0.11%)

USD 0.11B
CAPG:CA Capital Group Global Equi.. 1.94 % 0.00 %

+0.03 (+0.11%)

CAD 0.04B
XLVE:CA 1.93 % 0.00 %

N/A

N/A
HTEC Robo Global® Healthcare .. 1.88 % 0.00 %

+0.32 (+0.11%)

USD 0.05B
LABU Direxion Daily S&P Biotec.. 1.59 % 1.14 %

+3.55 (+0.11%)

USD 0.77B
FFND The Future Fund Active ET.. 1.57 % 0.00 %

-0.09 (0.11%)

USD 0.06B
ESMV iShares ESG MSCI USA Min .. 1.48 % 0.00 %

+0.13 (+0.11%)

USD 8.61M
FLXU:SW Franklin U.S. Equity UCIT.. 1.17 % 0.00 %

+0.27 (+0.11%)

N/A
THNZ:XETRA 1.03 % 0.00 %

N/A

N/A
BBH VanEck Biotech ETF 0.00 % 0.35 %

+2.18 (+0.11%)

USD 0.40B
DEF 0.00 % 0.59 %

N/A

N/A
FBT First Trust NYSE Arca Bio.. 0.00 % 0.57 %

+1.85 (+0.11%)

N/A
LABD Direxion Daily S&P Biotec.. 0.00 % 1.00 %

-0.26 (0.11%)

USD 0.06B
PBE Invesco Dynamic Biotechno.. 0.00 % 0.57 %

+0.52 (+0.11%)

N/A
SDG iShares MSCI Global Impac.. 0.00 % 0.49 %

+0.25 (+0.11%)

USD 0.19B
ZPW-U:CA BMO US Put Write ETF 0.00 % 0.00 %

-0.08 (0.11%)

N/A
BTEC:LSE iShares Nasdaq US Biotech.. 0.00 % 0.00 %

+0.04 (+0.11%)

N/A
BTEK:LSE iShares Nasdaq US Biotech.. 0.00 % 0.00 %

+0.05 (+0.11%)

N/A
BIGT:LSE L&G Pharma Breakthrough U.. 0.00 % 0.00 %

+0.15 (+0.11%)

N/A
BTEE:LSE iShares Nasdaq US Biotech.. 0.00 % 0.00 %

+0.03 (+0.11%)

N/A
VLQ:CA 0.00 % 0.40 %

N/A

N/A
XBI SPDR® S&P Biotech ETF 0.00 % 0.35 %

+1.20 (+0.11%)

N/A
ZBIO Zenas BioPharma, Inc. Com.. 0.00 % 0.95 %

-0.22 (0.11%)

N/A
AIEQ Amplify ETF Trust 0.00 % 0.75 %

-0.08 (0.11%)

USD 0.11B
HWWA:LSE HSBC Multi Factor Worldwi.. 0.00 % 0.00 %

+0.03 (+0.11%)

N/A
SMRG:LSE 0.00 % 0.00 %

N/A

N/A
SMRU:LSE 0.00 % 0.00 %

N/A

N/A
HWWD:LSE HSBC Multi Factor Worldwi.. 0.00 % 0.00 %

-0.07 (0.11%)

N/A
VMOM:LSE 0.00 % 0.00 %

N/A

N/A
XSD2:LSE db x-trackers ShortDAX x2.. 0.00 % 0.00 %

+1.86 (+0.11%)

USD 0.11B
ETLI:F 0.00 % 0.00 %

N/A

N/A
FLXU:F 0.00 % 0.00 %

N/A

N/A
SM8T:F 0.00 % 0.00 %

N/A

N/A
XAIN:F 0.00 % 0.00 %

N/A

N/A
ETLI:XETRA 0.00 % 0.00 %

N/A

N/A
ZGEN:CA 0.00 % 0.00 %

N/A

N/A
ZINN:CA 0.00 % 0.00 %

N/A

N/A
NVQ 0.00 % 0.00 %

N/A

N/A
CBUF:XETRA 0.00 % 0.00 %

N/A

N/A

Market Performance

  Market Performance vs. Industry/Classification (Biotechnology) Market Performance vs. Exchange (Nasdaq Global Select)
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
YTD  
Capital Gain 14.75% 80% B- 82% B
Dividend Return N/A N/A N/A N/A N/A
Total Return 14.75% 80% B- 82% B
Trailing 12 Months  
Capital Gain 9.86% 73% C 62% D
Dividend Return N/A N/A N/A N/A N/A
Total Return 9.86% 73% C 59% D-
Trailing 5 Years  
Capital Gain 88.54% 88% B+ 83% B
Dividend Return N/A N/A N/A N/A N/A
Total Return 88.54% 88% B+ 82% B
Average Annual (5 Year Horizon)  
Capital Gain 16.68% 64% D 70% C-
Dividend Return 16.68% 64% D 69% C-
Total Return N/A N/A N/A N/A N/A
Risk Return Profile  
Volatility (Standard Deviation) 26.74% 91% A- 67% D+
Risk Adjusted Return 62.36% 97% N/A 84% B
Market Capitalization 21.38B 100% F 99% N/A

Key Financial Ratios

  Ratio vs. Industry/Classification (Biotechnology) Ratio vs. Market (Nasdaq Global Select)
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
Market Value  
Price / Earning Ratio 32.57 21% 30%
Price/Book Ratio 7.61 20% 18%
Price / Cash Flow Ratio 33.61 3% 10%
Price/Free Cash Flow Ratio 220.35 1% 2%
Management Effectiveness  
Return on Equity -2.98% 94% 55%
Return on Invested Capital 22.53% 87% 88%
Return on Assets 12.05% 98% 97%
Debt to Equity Ratio N/A N/A N/A

Annual Financials (USD)

Quarterly Financials (USD)

Analyst Rating

Target Price Action Rating Action Analyst Rating Price Date

This is a composite scorecard based on the application of evaluation criteria deemed most important by analysts. This is not a buy or sell recommendation.

What to like:
Superior risk adjusted returns

This stock has performed well, on a risk adjusted basis, compared to its sector peers(for a hold period of at least 12 months) and is in the top quartile.

Superior return on assets

The company management has delivered better return on assets in the most recent 4 quarters than its peers, placing it in the top quartile.

Superior capital utilization

The company management has delivered better return on invested capital in the most recent 4 quarters than its peers, placing it in the top quartile.

Superior return on equity

The company management has delivered better return on equity in the most recent 4 quarters than its peers, placing it in the top quartile.

Low volatility

The stock’s annual returns have been stable and consistent compared to its sector peers(for a hold period of at least 12 months) and is in the top quartile. Although stability is good, also keep in mind it can limit returns.

High market capitalization

This is one of the largest entities in its sector and is among the top quartile. Such companies tend to be more stable.

Positive cash flow

The company had positive total cash flow in the most recent four quarters.

Positive free cash flow

The company had positive total free cash flow in the most recent four quarters.

Superior Earnings Growth

This stock has shown top quartile earnings growth in the previous 5 years compared to its sector.

High Gross Profit to Asset Ratio

This stock is in the top quartile compared to its peers on Gross Profit to Asset Ratio. This is a popular measure among value investors for showing superior returns in the long run.

What to not like:
Overpriced on cashflow basis

The stock is trading high compared to its peers on a price to cash flow basis. It is priced above the median for its sectors. Proceed with caution if you are considering to buy.

Overpriced compared to book value

The stock is trading high compared to its peers median on a price to book value basis.

Overpriced compared to earnings

The stock is trading high compared to its peers on a price to earning basis and is above the sector median.

Overpriced on free cash flow basis

The stock is trading high compared to its peers on a price to free cash flow basis. It is priced above the median for its sectors. Proceed with caution if you are considering to buy.